Trial Profile
72-week open label extension study (OLE) of iPrEx in HIV patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Feb 2022
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms iPrEx OLE
- 26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science
- 25 May 2015 New trial record